Marksans Pharma Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution".